Drug profile · INN
pexidartinib hydrochloride
TURALIO
pexidartinib hydrochloride (TURALIO) is a tyrosine-protein kinase receptor flt3 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — pexidartinib hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
pexidartinib hydrochloride (TURALIO) is a tyrosine-protein kinase receptor flt3 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Tyrosine-protein kinase receptor FLT3 inhibitor
Primary target: Macrophage colony-stimulating factor 1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is pexidartinib hydrochloride?
pexidartinib hydrochloride (TURALIO) is a tyrosine-protein kinase receptor flt3 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for pexidartinib hydrochloride?
TURALIO is a marketed brand name for pexidartinib hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pexidartinib hydrochloride?
pexidartinib hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.